[go: up one dir, main page]

CY2013045I1 - Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις - Google Patents

Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις

Info

Publication number
CY2013045I1
CY2013045I1 CY2013045C CY2013045C CY2013045I1 CY 2013045 I1 CY2013045 I1 CY 2013045I1 CY 2013045 C CY2013045 C CY 2013045C CY 2013045 C CY2013045 C CY 2013045C CY 2013045 I1 CY2013045 I1 CY 2013045I1
Authority
CY
Cyprus
Prior art keywords
cardiovascular disease
combinations including
renin inhibitor
synergic combinations
synergic
Prior art date
Application number
CY2013045C
Other languages
English (en)
Other versions
CY2013045I2 (el
Original Assignee
Novartis Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2013045(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Ag filed Critical Novartis Pharma Ag
Publication of CY2013045I2 publication Critical patent/CY2013045I2/el
Publication of CY2013045I1 publication Critical patent/CY2013045I1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CY2013045C 2000-11-17 2013-12-13 Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις CY2013045I1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds
EP20050015603 EP1602370B1 (en) 2000-11-17 2001-11-15 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
EP20010996377 EP1341533B1 (en) 2000-11-17 2001-11-15 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases

Publications (2)

Publication Number Publication Date
CY2013045I2 CY2013045I2 (el) 2015-11-04
CY2013045I1 true CY2013045I1 (el) 2015-11-04

Family

ID=9903412

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20061100519T CY1105603T1 (el) 2000-11-17 2006-04-13 Συνεργιστικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της ρενινης, για καρδιαγγειακες νοσους
CY20081100932T CY1108305T1 (el) 2000-11-17 2008-09-02 Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις
CY2009005C CY2009005I2 (el) 2000-11-17 2009-05-11 Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις
CY20131100889T CY1114829T1 (el) 2000-11-17 2013-10-10 Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις
CY2013045C CY2013045I1 (el) 2000-11-17 2013-12-13 Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις

Family Applications Before (4)

Application Number Title Priority Date Filing Date
CY20061100519T CY1105603T1 (el) 2000-11-17 2006-04-13 Συνεργιστικοι συνδυασμοι που περιλαμβανουν εναν αναστολεα της ρενινης, για καρδιαγγειακες νοσους
CY20081100932T CY1108305T1 (el) 2000-11-17 2008-09-02 Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις
CY2009005C CY2009005I2 (el) 2000-11-17 2009-05-11 Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις
CY20131100889T CY1114829T1 (el) 2000-11-17 2013-10-10 Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις

Country Status (31)

Country Link
US (4) US8168616B1 (el)
EP (7) EP2305231A1 (el)
JP (6) JP2004513920A (el)
KR (6) KR20080011355A (el)
CN (4) CN101264073A (el)
AT (2) ATE397445T1 (el)
AU (2) AU2002223680B2 (el)
BR (1) BR0115411A (el)
CA (2) CA2763223A1 (el)
CY (5) CY1105603T1 (el)
CZ (2) CZ299749B6 (el)
DE (3) DE60134349D1 (el)
DK (3) DK1602370T3 (el)
EC (1) ECSP034603A (el)
ES (4) ES2256335T3 (el)
GB (1) GB0028151D0 (el)
HU (2) HU230882B1 (el)
IL (3) IL155707A (el)
LU (2) LU91563I2 (el)
MX (1) MXPA03004358A (el)
NL (2) NL300385I1 (el)
NO (2) NO334002B1 (el)
NZ (6) NZ537691A (el)
PL (3) PL400915A1 (el)
PT (3) PT1602370E (el)
RU (2) RU2310443C2 (el)
SG (1) SG135969A1 (el)
SI (3) SI1602370T1 (el)
SK (1) SK287881B6 (el)
WO (1) WO2002040007A1 (el)
ZA (1) ZA200303497B (el)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002363087A1 (en) * 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
PL219032B1 (pl) * 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
GB0212410D0 (en) 2002-05-29 2002-07-10 Novartis Ag Organic compounds
WO2004002466A1 (en) * 2002-06-28 2004-01-08 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
AU2003250858A1 (en) * 2002-06-28 2004-01-19 Novartis Ag Use of organic compounds
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
CN102260188A (zh) 2003-11-26 2011-11-30 诺瓦提斯公司 有机化合物
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
PT1756037E (pt) * 2004-01-23 2011-02-25 Novartis Ag Derivados de aminoálcoois e a sua actividade como inibidores de renina
PT1735270E (pt) * 2004-01-23 2010-08-27 Novartis Ag Diamino-álcoois e sua utilização como inibidores da renina
EP1711456A2 (en) * 2004-01-23 2006-10-18 Speedel Experimenta AG Amino alcohol derivatives and their use as renin inhibitors
US20080161321A1 (en) * 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
PE20110121A1 (es) * 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
US7868036B2 (en) 2004-03-19 2011-01-11 Novartis Ag Organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
US20080085914A1 (en) * 2004-10-08 2008-04-10 David Louis Feldman Use Of Organic Compounds
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1877045A2 (en) * 2005-04-27 2008-01-16 Novartis AG Methods of treating atherosclerosis
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
PT1797885E (pt) * 2005-09-28 2008-05-20 Teva Pharma Combinações estáveis de besilato de amlodipina e cloridrato de benazepril
AU2006311723A1 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2008136317A (ru) * 2006-03-13 2010-04-20 Инсайсив Фармасьютикалз, Инк. (US) Способы и композиции для лечения диагностикой сердечной недостаточности
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
BRPI0721167A2 (pt) * 2006-12-15 2014-03-18 Novartis Ag Inibidores de renina para prevenção e tratamento de hipertensão em pacientes obesos.
US20080194626A1 (en) * 2007-02-14 2008-08-14 Gorczynski Richard J Antihypertensive drug combination
AU2008309058B2 (en) * 2007-09-28 2012-08-09 Novartis Ag Galenical formulations of Aliskiren and Valsartan
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
WO2009104939A2 (ko) 2008-02-22 2009-08-27 한올제약주식회사 약제학적 제제
CN101990428A (zh) 2008-04-10 2011-03-23 韩兀生物制药株式会社 药物制剂
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
KR101209319B1 (ko) 2008-04-29 2012-12-06 한올바이오파마주식회사 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
CA2755487A1 (en) 2009-03-20 2010-09-23 Novartis Ag Galenical formulations of a fixed dose combination of valsartan and aliskiren
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
WO2012152718A1 (en) 2011-05-06 2012-11-15 Farmicom Pharmaceutical Company D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
SG10201703789QA (en) * 2012-05-18 2017-06-29 Luoda Pharma Pty Ltd Liquid formulation
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
WO2016015812A1 (de) 2014-07-30 2016-02-04 Merck Patent Gmbh Direkt verpressbare polyvinylalkohole
SG11201903803UA (en) * 2016-10-27 2019-05-30 Damian Pharma Ag Aldosterone synthase inhibitor

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
FI77669C (fi) 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
DK0955294T3 (da) 1989-06-14 2004-02-02 Smithkline Beecham Corp Imidazolylalkensyre
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DE59107440D1 (de) 1990-02-19 1996-04-04 Ciba Geigy Ag Acylverbindungen
NZ237476A (en) 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
KR970005839B1 (ko) * 1990-05-11 1997-04-21 화이자 인코포레이티드 상승 치료효과를 얻기 위한 조성물 및 방법
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
WO1992003429A1 (en) * 1990-08-15 1992-03-05 Abbott Laboratories Renin inhibitors
WO1992010097A1 (en) 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
WO1992013564A1 (en) 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
IE920540A1 (en) 1991-02-21 1992-08-26 Sankyo Co 1-biphenylmethylimidazole derivatives, their preparation and¹their therapetuic use
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (el) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
DK0699069T3 (da) 1993-04-27 2002-05-27 Smithkline Beecham Corp Endothelinreceptorantagonister
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
DE59409631D1 (de) * 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
CA2169737C (en) 1993-08-18 2003-04-15 Kiyofumi Ishikawa Endothelin antagonistic heteroaromatic ring-fused cyclopentene derivatives
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
ATE219077T1 (de) 1994-08-19 2002-06-15 Abbott Lab Endothelin antagoniste
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (el) 1994-12-20 1997-08-21 Hoffmann La Roche
BR9606961A (pt) 1995-01-27 1997-11-04 Rhone Poulenc Rorer Ltd Composto processo para a sua preparação composição farmacêutica método par tratar um estado doentio capaz de ser amenizado pela administração de um inibidor de endotelina e aplicação do composto
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
RU2172735C2 (ru) 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
DE69733557T2 (de) 1996-04-04 2005-11-03 Banyu Pharmaceutical Co., Ltd. Endothelin-antagonisten zur behandlung von herzversagen
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
US6517871B1 (en) 1998-07-20 2003-02-11 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
JP2003511347A (ja) * 1999-03-19 2003-03-25 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド III型内皮細胞一酸化窒素合成酵素のHMG−CoA還元酵素阻害物質による上方制御
ATE370738T1 (de) 1999-11-09 2007-09-15 Pharmacia Corp Verwendung von eplerenon zur behandlung von restenose
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
PL219032B1 (pl) * 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
WO2004059136A1 (de) 2002-12-31 2004-07-15 Volkswagen Aktiengesellschaft Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffähige verbrennungskraftmaschine

Also Published As

Publication number Publication date
JP6577994B2 (ja) 2019-09-18
CZ299749B6 (cs) 2008-11-12
JP6089278B2 (ja) 2017-03-08
EP1602370A2 (en) 2005-12-07
CN100404024C (zh) 2008-07-23
BR0115411A (pt) 2004-08-17
RU2310443C2 (ru) 2007-11-20
PL361404A1 (en) 2004-10-04
KR20080097488A (ko) 2008-11-05
ATE317692T1 (de) 2006-03-15
EP2305232A1 (en) 2011-04-06
NO334002B1 (no) 2013-11-11
KR20110063596A (ko) 2011-06-10
NO2013019I2 (no) 2013-12-17
ES2734523T3 (es) 2019-12-10
PT1341533E (pt) 2006-06-30
EP2305232B1 (en) 2019-07-17
DE122009000021I1 (de) 2009-08-06
JP6603757B2 (ja) 2019-11-06
JP6373931B2 (ja) 2018-08-15
KR20080096715A (ko) 2008-10-31
US8168616B1 (en) 2012-05-01
EP1930000A1 (en) 2008-06-11
HK1089356A1 (en) 2006-12-01
PL400915A1 (pl) 2012-12-17
CA2428647A1 (en) 2002-05-23
EP1915993A1 (en) 2008-04-30
HU1400409D0 (hu) 2003-09-29
DE60117295D1 (de) 2006-04-20
KR20080011355A (ko) 2008-02-01
DE60117295T2 (de) 2006-08-17
JP2009235107A (ja) 2009-10-15
SK5842003A3 (en) 2003-11-04
ES2256335T3 (es) 2006-07-16
CY1108305T1 (el) 2012-01-25
SK287881B6 (sk) 2012-02-03
PT1602370E (pt) 2008-09-10
ATE397445T1 (de) 2008-06-15
JP2013213061A (ja) 2013-10-17
CY2013045I2 (el) 2015-11-04
EP1602370A3 (en) 2005-12-14
JP2018131465A (ja) 2018-08-23
NZ550897A (en) 2008-03-28
CN101091703A (zh) 2007-12-26
DK1341533T3 (da) 2006-05-08
SI1915993T1 (sl) 2013-10-30
CY2009005I1 (el) 2012-01-25
KR20030051753A (ko) 2003-06-25
JP2018030894A (ja) 2018-03-01
US20120016035A1 (en) 2012-01-19
IL155707A (en) 2012-02-29
HUP0301841A3 (en) 2010-07-28
WO2002040007A1 (en) 2002-05-23
HK1059212A1 (en) 2004-06-25
IL155707A0 (en) 2003-11-23
SI1602370T1 (sl) 2008-10-31
MXPA03004358A (es) 2003-08-19
DE60134349D1 (de) 2008-07-17
ECSP034603A (es) 2003-06-25
PL400914A1 (pl) 2012-12-17
LU92315I2 (fr) 2014-01-27
NZ550898A (en) 2008-07-31
AU2002223680B2 (en) 2005-04-07
ES2308347T3 (es) 2008-12-01
NL300385I1 (nl) 2009-07-01
CN101264072A (zh) 2008-09-17
US20120010295A1 (en) 2012-01-12
CA2763223A1 (en) 2002-05-23
NZ525795A (en) 2005-03-24
CY1105603T1 (el) 2010-07-28
DK1602370T3 (da) 2008-09-22
IL212075A (en) 2013-08-29
NL301005I2 (nl) 2019-10-29
US9023894B2 (en) 2015-05-05
CN1474690A (zh) 2004-02-11
CY2009005I2 (el) 2012-01-25
CY1114829T1 (el) 2015-11-04
HU230882B1 (hu) 2018-11-29
GB0028151D0 (en) 2001-01-03
SI1341533T1 (sl) 2006-08-31
EP2305231A1 (en) 2011-04-06
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
EP1341533A1 (en) 2003-09-10
LU91563I2 (fr) 2009-07-06
NO2013019I1 (no) 2014-06-02
RU2006132668A (ru) 2008-03-20
US9023893B2 (en) 2015-05-05
NZ537691A (en) 2007-01-26
JP2004513920A (ja) 2004-05-13
CZ305341B6 (cs) 2015-08-05
US8618174B2 (en) 2013-12-31
KR101258365B1 (ko) 2013-04-30
CN101264073A (zh) 2008-09-17
NZ568764A (en) 2009-11-27
EP1341533B1 (en) 2006-02-15
IL217847A0 (en) 2012-03-29
EP2305233A1 (en) 2011-04-06
PL227576B1 (pl) 2017-12-29
AU2368002A (en) 2002-05-27
EP1602370B1 (en) 2008-06-04
NO20032233L (no) 2003-05-16
NO20032233D0 (no) 2003-05-16
US20120004312A1 (en) 2012-01-05
IL212075A0 (en) 2011-06-30
DK1915993T3 (da) 2013-10-14
KR101008752B1 (ko) 2011-01-14
EP1915993B1 (en) 2013-07-10
RU2346703C2 (ru) 2009-02-20
SG135969A1 (en) 2007-10-29
ES2429292T3 (es) 2013-11-14
JP2017019876A (ja) 2017-01-26
HUP0301841A2 (hu) 2003-09-29
NL301005I1 (el) 2019-09-10
ZA200303497B (en) 2004-04-28
KR20100114904A (ko) 2010-10-26
HK1115544A1 (en) 2008-12-05

Similar Documents

Publication Publication Date Title
CY2013045I2 (el) Συνεργιστικοι συνδυασμοι που περιλαμβανουν αναστολεα ρενινης για καρδιαγγειακες παθησεις
IS6714A (is) Fjölbrigði epóþílon hliðstæðu
ATE524441T1 (de) Vla-4-inhibitoren
NO20035000D0 (no) Fremgangsmåte for å ekspandere et sandfilter
DE60123294D1 (de) Diazepan Derivate als Faktor X Inhibitor
NO20023261D0 (no) Småbok
FI20000369L (fi) Menetelmä kefalokuvauksen suorittamiseksi
DE60128885D1 (de) Magnetoresistiver Wandler
DE60126877D1 (de) D/A-Wandler
EE200300116A (et) Efektiivne meetod faktori Xa inhibiitori valmistamiseks
SG119168A1 (en) Utilization of at least one aminopeptidase inhibitor
DE60031109D1 (de) Übertragsicherstellungsaddierer
FR2811262B1 (fr) Grattoir a chasse-clous
DE60132468D1 (de) Alen-lanosterol zyklase inhibitoren
FR2848281B1 (fr) Robinet a boisseau
NO20024611D0 (no) Fremgangsmåte for å profilbestemme et planteekstrakt
DK200100180U3 (da) Nedgangsbrønd
DE50010748D1 (de) Rotationsunabhängige Betätigung eines Maschinenteils
ID29372A (id) Oksamida sebagai inhibitor impdh
DE60139327D1 (de) Lademechanismus eines plattenabspielgeräts
ITMN20000012A0 (it) Caldaia a legna
NO20025654D0 (no) Anordning ved en seng
FR2790057B1 (fr) Coupleur a billes
ITMI20010368V0 (it) Cartoncino per gioco a coppie
IT250521Y1 (it) Puntello a crocera multiuso